EPO and acquired polycythemia vera: NT157 (3.2 μM) treatment significantly reduced erythropoietin-independent colony formation in peripheral (n = 2) and bone marrow (n = 1) mononuclear cells from PV patients by an average of 29% (p < 0.05), and the range was 14–47%.